Annual General Meeting of Active Biotech AB
May 23 2019 - 02:00PM
PRESS RELEASE
The Annual General Meeting of Active Biotech was
held on May 23, 2019.
In accordance with the Board of Directors'
proposal, it was resolved that no dividend would be paid.
The members of the Board and the President were
discharged from liability with respect to their management of the
Company for 2018.
In accordance with the Election
Committee's proposal, the Board members Peter Sjöstrand and Peter
Thelin were re-elected. Furthermore, the Meeting resolved on the
appointment of Michael Shalmi and Uli Hacksell as new members of
the Board. The Meeting also resolved on the appointment of Michael
Shalmi as Chairman of the Board. KPMG AB was re-elected as
auditor.
In accordance with the Election
Committee's proposal, the Meeting resolved that fees payable to the
Board shall amount to SEK 500,000 to the Chairman of the Board and
SEK 200,000 to each of the other Board members who are not
employees of the Company. Furthermore, the Meeting resolved that
Michael Shalmi may also receive remuneration on market terms for
work performed for the Company outside the scope of the Board
work.
Furthermore, the Meeting resolved, in accordance
with the Election Committee's proposal, that the Election Committee
shall be composed of representatives for the three largest owners,
as per the end of September, 2019, as well as the Chairman of the
Board.
The Meeting approved the Board's proposal
concerning guidelines for remuneration to the President and other
senior executives. The guidelines conform to the principles applied
to date.
It was further resolved to amend the Company's
articles of association in accordance with the Board's
proposal.
In accordance with the Board's proposal, the
Meeting finally resolved to authorize the Board to, for a period
that does not extend past the date of the next Annual General
Meeting, with or without pre-emptive rights for the shareholders,
resolve on the issue of new shares and/or convertibles,
corresponding to not more than 30 percent of the total number of
shares in the Company after utilization of the authorization.
Lund May 23, 2019
Active Biotech AB (publ)
Helén Tuvesson
President and CEO
For further information, please
contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA (naptumumab), an immunotherapy, in development for
cancer indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information was submitted
for publication, through the agency of the contact person set out
above, at 20:00 p.m. CET on May 23, 2019.
190523_AGM
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024